Beginning in the late 1980s, a large increase in incidence rates for prostate cancer occurred
in association with increased prostate-specific antigen (PSA) screening. In New Mexico, the …

BACKGROUND In the 1980s, prostate specific antigen (PSA) came into wide use as a
prostate carcinoma screening and detection method in the United States. Following the …

Prostate specific antigen (PSA) screening was introduced to detect prostate cancer at an
early stage and to reduce prostate cancer‐specific mortality. Until results from clinical trials …

The ultimate utility of the serum prostate specific antigen (PSA) assay as a screening test for
reducing prostate cancer mortality has been an area of intense controversy since its …

With the publication of the long-term results of two randomized screening trials and updates
to screening guidelines from many organizations, the past 2 years have been eventful in the …

Evidence demonstrating the burden of prostate cancer on men in the United States is
incontrovertible; less compelling is evidence of benefit from early detection efforts. Thus is …

André N. Vis based screening for prostate cancer resulted in a reduction in prostate cancer
mortality of up to 70% in those subjected to screening compared with those who were not …

Background: Physicians have speculated that prostate-specific antigen (PSA) screening
may be responsible for the reduction in prostate cancer mortality observed in the late 1990s …

The incidence of prostate cancer has increased considerably over the past two decades,
partly due to the increased detection of subclinical cases. In southeastern Netherlands, a …

The age-adjusted incidence of prostate cancer now surpasses that of all other cancers
among men in the United States (1). It was estimated for 1991 that 122,000 new prostate …